ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Merus NV

Merus NV (2GH)

42.00
0.60
( 1.45% )
Updated: 15:40:45
Realtime Data

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
42.00
Bid
40.40
Ask
40.80
Volume
557
41.40 Day's Range 42.20
21.40 52 Week Range 58.50
Previous Close
41.40
Open
41.80
Last Trade
5
@
42
Last Trade Time
08:29:41
Average Volume (3m)
150
Financial Volume
-
VWAP
-

2GH Latest News

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC Studie mit Petosemtamab in Kombination mit Pembrolizumab bei 1L...

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m...

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-3.6-7.8947368421145.645.639.650741.91558185DE
4-6.2-12.863070539448.248.239.617842.85404101DE
12-3.2-7.079646017745.251.539.615046.14471602DE
26-7-14.28571428574957.539.616948.03577184DE
522090.90909090912258.521.39999917944.24911102DE
15618.276.470588235323.858.51917141.97393714DE
26018.276.470588235323.858.51917141.97393714DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CXFChimerix Inc
2.675 €
(228.62%)
350.88k
UQ1Uniqure NV
15.40 €
(122.74%)
47.73k
XE7CCardiff Oncology Inc
3.645 €
(57.79%)
147.73k
9DRGlimpse Group
1.20 €
(52.87%)
14.47k
C62Chariot Limited
0.03 €
(39.53%)
13.55k
0PV2Moovly Media Inc
0.0025 €
(-58.33%)
560
KEHChinese People Holdings Co Ltd
0.0015 €
(-50.00%)
42.7k
PA8Paion AG
0.0132 €
(-45.90%)
844
1R6Alset AI Ventures Inc
0.048 €
(-31.91%)
101.8k
1R3Izotropic Corp
0.0222 €
(-30.63%)
1,000
AXIAtos SE
0.0023 €
(-14.81%)
728.66M
D7GNel ASA
0.2724 €
(0.93%)
4.19M
PF8European Lithium Limited
0.0256 €
(-4.48%)
2.07M
3CPXiaomi Corporation
3.8075 €
(-2.25%)
2.02M
PLUNPlug Power Inc
2.3765 €
(-5.92%)
1.31M

Discussion

View Full Feed
Hunterdave Hunterdave 4 minutes ago
This is a flip or trade at best currently.
What percentage of people have a Clue what this company is thinking of? AND..this is 3 YEARS LATER..
I have shares but have kissed them goodbye
Carry On...
HMBL
bbotcs bbotcs 4 minutes ago
r59: WBA
Very interesting. Thank you for posting the article. I liked the pic of the Walgreen's in Nashville in 1957! I am not sure the company would benefit from being owned by Sycamore. They invest in retail businesses, and Walgreen's is more than retail--it is a pharmacy company.
CVS WBA
manysevens manysevens 5 minutes ago
SPRC .27's nibbling jic :-)
SPRC
Gmenfan Gmenfan 5 minutes ago
Merrick Garland Is The Worst Attorney General In American History

For once, left and right agree: Merrick Garland is the worst.

I was surprised when I first saw this article from MSNBC and CNN contributor Dean Obeidallah declaring Garland to be “America’s Worst Attorney
chemist72 chemist72 5 minutes ago
Thanks for the link. At least we know the schedule for the hearings.

There are 18 parties scheduled to make presentations to the court. Each participant can submit up to a 25-page brief. That would be a maximum of 450 pages that the court has to wade through before any judgement coul
ILST
weedtrader420 weedtrader420 5 minutes ago
WOOHOOOOOOOOOOOOOOO
XRPUSD
Gmenfan Gmenfan 5 minutes ago
Merrick Garland Is The Worst Attorney General In American History

For once, left and right agree: Merrick Garland is the worst.

I was surprised when I first saw this article from MSNBC and CNN contributor Dean Obeidallah declaring Garland to be “America’s Worst Attorney
Golden Cross Golden Cross 5 minutes ago
To All: There is NO RS planned, being planned or needed as one poster keeps posting here... Just wanted to clear that up and you can find out information like this by reading the filings... GLTA... $ILLR
ILLR
pdmihopefull pdmihopefull 5 minutes ago
You started this by calling me Junior.... lmao,... senior citizen...lol
HMBL
Jinyinh666 Jinyinh666 5 minutes ago
When they lowered AS to 200M, they thought that’s sufficient to carry them through up listing. We are disappointed in the audit delays, so is Nils🤣
BMXI
Jinyinh666 Jinyinh666 5 minutes ago
When they lowered AS to 200M, they thought that’s sufficient to carry them through up listing. We are disappointed in the audit delays, so is Nils🤣
BMXI
Noghawbuck Noghawbuck 5 minutes ago
Susan will probably get top remodeler of the year award Ben will get best donkey at the show and Roger will get runner up ! Can’t wait till next year !! What a show!I love 🤡
FUNN
RIGATONI RIGATONI 5 minutes ago
Beauty move! ~Rig
Lime Time Lime Time 5 minutes ago
End of year almost here and nobody dumping. Peeps holding shares strong.
CNNA
WinstonCup WinstonCup 5 minutes ago
Absolutely, telling untruths will come around and bite ya in the @ss
WDLF
BlazingStocks BlazingStocks 6 minutes ago
$FAVO - This recognition from Business Honor serves as both a testament to the company's achievements and a catalyst for ongoing growth and transformation. Moving forward, FAVO Capital remains dedicated to nurturing strong partnerships and delivering cutting-edge financing solutions that empower sma
FAVO
underpar71 underpar71 6 minutes ago
I believe you would see it in price and volume. Right now a move and close above the 100DMA would be significant as it hasn't happened since January. But, this is also a .30 stock on the OTC, so there's that. A week or so of small movement above .32-.33 might get us a 50DMA crossing the 100DMA, whi
NWBO
dstock07734 dstock07734 6 minutes ago
Has Merck KGaA struck a deal with another company which finished the trial on CSF1R inhibitor and is ready to file for RA approval?
NWBO
Momentum_Scalper Momentum_Scalper 6 minutes ago
HOD close would be 👍🏻
BCDS
Brocool Brocool 6 minutes ago
Auri Inc representatives and Brand Ambassadors are visiting several factories and fulfilment centers for strategic relationships and possible future acquisitions. The company is designing a program and a pathway to enable its crypto currency tokens AURI and BDGR to be used as payment for its product
AURI BDGR
abka abka 6 minutes ago
Free fall
AMRN
elks elks 6 minutes ago
Right we just got stronger here....
AZRH
don estaban don estaban 7 minutes ago
Ok skulls I am picking what I can down here as well ,we will see !
MVNT
koolmc koolmc 7 minutes ago
yep holding steady here
KRTL

Your Recent History

Delayed Upgrade Clock